COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL FOR PREVIOUSLY UNTREATED PATIENTS WITH METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER IN ENGLAND

被引：0
|
作者：
Harding, T. [1 ]
Dawson, H. [1 ]
Insinga, R. [2 ]
Topaloudi, V [1 ]
Ejzykowicz, F. [3 ]
Zhang, Y. [4 ]
机构：
[1] Merck Sharp & Dohme Ltd, Hoddesdon, Hrt, England
[2] Merck & Co Inc, N Wales, PA USA
[3] Merck & Co Inc, Kenilworth, NJ USA
[4] MSD Belgium, Brussels, Belgium
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN194
引用
收藏
页码：S473 / S473
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN COMBINATION WITH PLATINUM CHEMOTHERAPY AND PEMETREXED FOR PREVIOUSLY UNTREATED PATIENTS WITH METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN ENGLAND
    Harding, T.
    Insinga, R.
    Dawson, H.
    Bates, B. E.
    Arunachalam, A.
    Vandormael, K.
    [J]. VALUE IN HEALTH, 2019, 22 : S473 - S473
  • [2] Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
    Zeng, Xiaohui
    Wan, Xiaomin
    Peng, Liubao
    Peng, Ye
    Ma, Fang
    Liu, Qiao
    Tan, Chongqing
    [J]. BMJ OPEN, 2019, 9 (12): : e031019
  • [3] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB COMPARED TO PEMBROLIZUMAB IN PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER PATIENTS
    Huang, Y.
    Wang, Y.
    Diaby, K.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S414 - S414
  • [4] Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer
    Aziz, Mohamed Ismail Abdul
    Tan, Ling Eng
    Tan, Wan Hui Gloria
    Toh, Chee-Keong
    Loke, Lydia Pui Yee
    Pearce, Fiona
    Ng, Kwong
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (09) : 952 - 960
  • [5] Comparative analysis of carboplatin and paclitaxel combination chemotherapy schedules in previously untreated patients with advanced non-small cell lung cancer
    Shimizu, Toshiki
    Yokoi, Takashi
    Tamaki, Takeshi
    Kibata, Kayoko
    Inagaki, Noriko
    Nomura, Shosaku
    [J]. ONCOLOGY LETTERS, 2013, 5 (03) : 761 - 767
  • [6] Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin–paclitaxel
    Oscar Arrieta
    Pablo Anaya
    Vicente Morales-Oyarvide
    Laura Alejandra Ramírez-Tirado
    Ana C. Polanco
    [J]. The European Journal of Health Economics, 2016, 17 : 855 - 863
  • [7] Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients
    Zheng, Hanrui
    Zeng, Ya
    Wen, Feng
    Hu, Ming
    [J]. FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [8] Cost-effectiveness of first-line pembrolizumab plus chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC).
    Kim, Ashley
    Devine, Beth
    Roth, Joshua A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) IN COMBINATION WITH CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE
    Chouaid, C.
    Bensimon, L.
    Tardu, J.
    Millier, A.
    Insinga, R.
    Rai, A.
    Levy-Bachelot, L.
    Levy, P.
    [J]. VALUE IN HEALTH, 2020, 23 : S433 - S433
  • [10] Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel
    Arrieta, Oscar
    Anaya, Pablo
    Morales-Oyarvide, Vicente
    Alejandra Ramirez-Tirado, Laura
    Polanco, Ana C.
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2016, 17 (07): : 855 - 863
12345